- Home
- BTE vs DNLI Comparison
BTE vs DNLI Comparison
Compare BTE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | DNLI |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BTE | DNLI |
|---|---|---|
| Price | $3.39 | $19.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.82 |
| AVG Volume (30 Days) | ★ 18.9M | 1.7M |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,194,819,404.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,897.53 |
| P/E Ratio | $17.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $10.57 |
| 52 Week High | $3.63 | $24.35 |
Technical Indicators
Market Signals| Indicator | BTE | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 57.16 |
| Support Level | $3.36 | $19.76 |
| Resistance Level | $3.57 | $23.77 |
| Average True Range (ATR) | 0.13 | 1.40 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 55.42 | 56.98 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.